{"id":"her3","name":"HER3","symbol":"ERBB3","route":"/targets/her3/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3431","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000065361","uniprot":"https://www.uniprot.org/uniprotkb/P21860/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P21860","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5838","open-targets":"https://platform.opentargets.org/target/ENSG00000065361","civic":"https://civicdb.org/genes/2065/summary","oncokb":"https://www.oncokb.org/gene/ERBB3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERBB3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=ERBB3","depmap":"https://depmap.org/portal/gene/ERBB3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000065361-ERBB3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2065","omim":"https://www.omim.org/entry/190151"}],"products":[{"id":"env-501","name":"ENV-501","status":"phase-2","modality":"ADC","route":"/drugs/env-501/"},{"id":"hmbd-001","name":"HMBD-001","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/hmbd-001/"},{"id":"izalontamab-brengitecan","name":"Izalontamab brengitecan","status":"phase-3","modality":"Bispecific ADC","route":"/drugs/izalontamab-brengitecan/"},{"id":"patritumab-deruxtecan","name":"Patritumab deruxtecan","status":"phase-3","modality":"ADC","route":"/drugs/patritumab-deruxtecan/"},{"id":"pertuzumab","name":"Pertuzumab","status":"approved","modality":"Monoclonal antibody (anti-HER2, dimerisation domain)","route":"/drugs/pertuzumab/"},{"id":"sys6023","name":"SYS6023","status":"phase-2","modality":"ADC","route":"/drugs/sys6023/"},{"id":"yl202","name":"YL202","status":"phase-3","modality":"antibody-drug conjugate (ADC)","route":"/drugs/yl202/"},{"id":"zenocutuzumab","name":"Zenocutuzumab","status":"approved","modality":"Bispecific antibody (HER2×HER3)","route":"/drugs/zenocutuzumab/"}],"trials":[{"id":"bl-b01d1-307","name":"BL-B01D1-307","nct":"NCT06382142","phase":"3","status":"positive"},{"id":"panku-esophagus01","name":"PANKU-Esophagus01 (BL-B01D1-305)","nct":"NCT06304974","phase":"3","status":"positive"},{"id":"her2climb-05","name":"HER2CLIMB-05","nct":"NCT05132582","phase":"3","status":"positive"},{"id":"herthena-lung02","name":"HERTHENA-Lung02","nct":"NCT05338970","phase":"3","status":"mixed"},{"id":"patina","name":"PATINA","nct":"NCT02947685","phase":"3","status":"positive"},{"id":"nct02003209","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","nct":"NCT02003209","phase":"3","status":"completed"},{"id":"kristine","name":"KRISTINE","nct":"NCT02131064","phase":"3","status":"negative"},{"id":"train-2","name":"TRAIN-2","nct":"NCT01996267","phase":"3","status":"positive"},{"id":"aphinity","name":"APHINITY","nct":"NCT01358877","phase":"3","status":"positive"},{"id":"cleopatra","name":"CLEOPATRA","nct":"NCT00567190","phase":"3","status":"positive"},{"id":"nct07060807","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","nct":"NCT07060807","phase":"3","status":"recruiting"},{"id":"nct06057610","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","nct":"NCT06057610","phase":"3","status":"active"},{"id":"nct02320435","name":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","nct":"NCT02320435","phase":"3","status":"active"},{"id":"nct07502300","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","nct":"NCT07502300","phase":"3","status":"recruiting"},{"id":"nct07640789","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","nct":"NCT07640789","phase":"3","status":"recruiting"},{"id":"nct06382129","name":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU","nct":"NCT06382129","phase":"3","status":"active"},{"id":"nct06118333","name":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)","nct":"NCT06118333","phase":"3","status":"active"},{"id":"nct06382116","name":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","nct":"NCT06382116","phase":"3","status":"active"},{"id":"nct06994195","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","nct":"NCT06994195","phase":"3","status":"recruiting"},{"id":"nct06500026","name":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","nct":"NCT06500026","phase":"3","status":"active"},{"id":"nct06838273","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","nct":"NCT06838273","phase":"3","status":"recruiting"},{"id":"nct07729956","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","nct":"NCT07729956","phase":"3","status":"planned"},{"id":"nct07518173","name":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M","nct":"NCT07518173","phase":"3","status":"recruiting"},{"id":"nct07196774","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","nct":"NCT07196774","phase":"3","status":"active"},{"id":"nct05802225","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","nct":"NCT05802225","phase":"3","status":"active"},{"id":"nct03803553","name":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","nct":"NCT03803553","phase":"3","status":"active"},{"id":"nct07416994","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","nct":"NCT07416994","phase":"3","status":"recruiting"},{"id":"nct04208178","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","nct":"NCT04208178","phase":"3","status":"active"},{"id":"nct07680790","name":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C","nct":"NCT07680790","phase":"3","status":"planned"},{"id":"nct06490536","name":"The Sagittarius Trial","nct":"NCT06490536","phase":"3","status":"recruiting"},{"id":"nct04514419","name":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","nct":"NCT04514419","phase":"3","status":"active"},{"id":"nct07461454","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","nct":"NCT07461454","phase":"3","status":"recruiting"},{"id":"nct07739199","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","nct":"NCT07739199","phase":"2/3","status":"planned"},{"id":"nct07739186","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","nct":"NCT07739186","phase":"2/3","status":"planned"},{"id":"nct07642024","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","nct":"NCT07642024","phase":"2/3","status":"recruiting"},{"id":"nct06891833","name":"A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea","nct":"NCT06891833","phase":"2/3","status":"recruiting"},{"id":"nct07294508","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","nct":"NCT07294508","phase":"2/3","status":"recruiting"},{"id":"determine-arm04","name":"DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers","nct":"NCT05786716","phase":"2/3","status":"recruiting"},{"id":"izabright-breast01","name":"IZABRIGHT-Breast01","nct":"NCT06926868","phase":"2/3","status":"recruiting"},{"id":"nct07100080","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","nct":"NCT07100080","phase":"2/3","status":"recruiting"},{"id":"i-spy-2","name":"I-SPY 2","nct":"NCT01042379","phase":"platform","status":"active"},{"id":"determine-trial","name":"DETERMINE","nct":"NCT05722886","phase":"platform","status":"recruiting"},{"id":"nct02912949","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","nct":"NCT02912949","phase":"2","status":"active"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"nct04619004","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","nct":"NCT04619004","phase":"2","status":"active"},{"id":"phergain","name":"PHERGain","nct":"NCT03161353","phase":"2","status":"positive"},{"id":"triumph","name":"TRIUMPH","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"mypathway","name":"MyPathway","nct":"NCT02091141","phase":"2","status":"completed"},{"id":"heracles","name":"HERACLES","nct":"NCT03225937","phase":"2","status":"positive"},{"id":"neosphere","name":"NeoSphere","nct":"NCT00545688","phase":"2","status":"positive"},{"id":"nct07597629","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","nct":"NCT07597629","phase":"2","status":"recruiting"},{"id":"nct07102381","name":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","nct":"NCT07102381","phase":"2","status":"recruiting"},{"id":"nct06439771","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","nct":"NCT06439771","phase":"2","status":"recruiting"},{"id":"nct00781612","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","nct":"NCT00781612","phase":"2","status":"active"},{"id":"nct07054567","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","nct":"NCT07054567","phase":"2","status":"recruiting"},{"id":"nct05880706","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","nct":"NCT05880706","phase":"2","status":"active"},{"id":"nct07827261","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","nct":"NCT07827261","phase":"2","status":"planned"},{"id":"nct06498986","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","nct":"NCT06498986","phase":"2","status":"recruiting"},{"id":"nct06787664","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","nct":"NCT06787664","phase":"2","status":"active"},{"id":"nct05924841","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","nct":"NCT05924841","phase":"2","status":"recruiting"},{"id":"nct05990803","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","nct":"NCT05990803","phase":"2","status":"recruiting"},{"id":"nct06006169","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor","nct":"NCT06006169","phase":"2","status":"recruiting"},{"id":"nct06437509","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","nct":"NCT06437509","phase":"2","status":"recruiting"},{"id":"nct06475300","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","nct":"NCT06475300","phase":"2","status":"recruiting"},{"id":"nct06437522","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","nct":"NCT06437522","phase":"2","status":"recruiting"},{"id":"nct06445400","name":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ","nct":"NCT06445400","phase":"2","status":"active"},{"id":"nct06172478","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","nct":"NCT06172478","phase":"2","status":"recruiting"},{"id":"nct06731907","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","nct":"NCT06731907","phase":"2","status":"recruiting"},{"id":"nct05956587","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other","nct":"NCT05956587","phase":"2","status":"recruiting"},{"id":"nct06008054","name":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric ","nct":"NCT06008054","phase":"2","status":"recruiting"},{"id":"nct07202364","name":"A Study of YL202 in Patients With Advanced Solid Tumors","nct":"NCT07202364","phase":"2","status":"recruiting"},{"id":"nct06107686","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","nct":"NCT06107686","phase":"2","status":"recruiting"},{"id":"nct06178159","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","nct":"NCT06178159","phase":"2","status":"recruiting"},{"id":"nct04425018","name":"MARGetuximab Or Trastuzumab (MARGOT)","nct":"NCT04425018","phase":"2","status":"active"},{"id":"nct07527806","name":"Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging","nct":"NCT07527806","phase":"2","status":"planned"},{"id":"nct07825753","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","nct":"NCT07825753","phase":"2","status":"planned"},{"id":"nct06797635","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","nct":"NCT06797635","phase":"2","status":"recruiting"},{"id":"nct07129018","name":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","nct":"NCT07129018","phase":"2","status":"planned"},{"id":"nct07286149","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","nct":"NCT07286149","phase":"1/2","status":"recruiting"},{"id":"nct05593094","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","nct":"NCT05593094","phase":"1/2","status":"active"},{"id":"nct06956690","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","nct":"NCT06956690","phase":"1/2","status":"recruiting"},{"id":"nct05150691","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","nct":"NCT05150691","phase":"1/2","status":"recruiting"},{"id":"nct04538742","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","nct":"NCT04538742","phase":"1/2","status":"active"},{"id":"nct05910827","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","nct":"NCT05910827","phase":"1/2","status":"recruiting"},{"id":"nct07140393","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","nct":"NCT07140393","phase":"1/2","status":"recruiting"},{"id":"nct06941272","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","nct":"NCT06941272","phase":"1/2","status":"recruiting"},{"id":"nct07169994","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","nct":"NCT07169994","phase":"1/2","status":"recruiting"},{"id":"nct06771622","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","nct":"NCT06771622","phase":"1/2","status":"active"},{"id":"nct06596694","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","nct":"NCT06596694","phase":"1/2","status":"recruiting"},{"id":"nct06686394","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","nct":"NCT06686394","phase":"1/2","status":"recruiting"},{"id":"nct06469944","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","nct":"NCT06469944","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["bms","cspc","daiichi-sankyo","hummingbird-bioscience","medilink","merck","merus","pathos-ai","roche-genentech","systimmune"],"keyPapers":["paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025","paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019","paper-narayan-gallbladder-regional-mutations-cancer-2019","paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","paper-li-gallbladder-exome-erbb-nat-genet-2014","paper-yarden-sliwkowski-erbb-network-nrmcb-2001"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"egfr-tki","mechanism":"On-target EGFR C797S","category":"on-target"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}